about
Lack of adenomatous polyposis coli protein correlates with a decrease in cell migration and overall changes in microtubule stabilityEpothilones: From discovery to clinical trialsA novel microtubule inhibitor 4SC-207 with anti-proliferative activity in taxane-resistant cellsStructure of the epimerization domain of tyrocidine synthetase AIxabepilone for the treatment of solid tumors: a review of clinical dataUnderstanding the basis of drug resistance of the mutants of αβ-tubulin dimer via molecular dynamics simulationsStabilized Polymer Micelles for the Development of IT-147, an Epothilone D Drug-Loaded FormulationPhase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study.Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer.Interspecies scaling of a camptothecin analogue: human predictions for intravenous topotecan using animal data.Other paradigms: growth rate constants and tumor burden determined using computed tomography data correlate strongly with the overall survival of patients with renal cell carcinoma.Enzymatic synthesis of epothilone A glycosidesRole of natural product diversity in chemical biology.Investigation of antitumor effects of synthetic epothilone analogs in human myeloma models in vitro and in vivo.Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins.Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.Current status of maintenance therapy for advanced ovarian cancer.Ixabepilone development across the breast cancer continuum: a paradigm shift.Novel microtubule-targeting agents - the epothilones.Ixabepilone (ixempra), a therapeutic option for locally advanced or metastatic breast cancer.Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology groupGenomic characteristics and comparative genomics analysis of Penicillium chrysogenum KF-25.Drugs that target dynamic microtubules: a new molecular perspectiveThe epothilones: new therapeutic agents for castration-resistant prostate cancer.Drug discovery from natural sources.Synthesis by ring-closing metathesis and cytotoxic evaluation of novel thienylmacrolactones.Chronic exposure to paclitaxel diminishes phosphoinositide signaling by calpain-mediated neuronal calcium sensor-1 degradation.Chemotherapy in Androgen-Independent Prostate Cancer (AIPC): What's next after taxane progression?Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone.Microtubule drugs: action, selectivity, and resistance across the kingdoms of life.The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium.Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates.Novel agents and targets in managing patients with metastatic prostate cancer.The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivoChemotherapy in Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: An Overview.Locoregional interaction of ixabepilone (ixempra) after breast cancer radiation.Breast Cancer Cell Lines Exhibit Differential Sensitivities to Microtubule-targeting Drugs Independent of Doubling Time.Emerging drugs for the treatment of soft tissue sarcomas.Treatment of neuroblastoma and rhabdomyosarcoma using RGD-modified liposomal formulations of patupilone (EPO906).Novel strategies for treating relapsed/refractory urothelial carcinoma.
P2860
Q24338380-02DC6A03-F7E1-4AD7-8C29-2EE1ED152856Q27005747-DEC320D7-AC67-4A6D-B561-68952731E6F8Q27302772-B8EA5754-D47A-43BB-B429-4CEF5AE8A146Q27690209-AF4CF689-9BF1-48A6-AD40-4D4183A2E832Q28271570-6B528C93-6860-4883-9B75-BB7B4C6DBDB0Q28482107-C2224FC5-37B4-4BF6-A23C-B7A4C769ACACQ28817437-2C43A287-E59B-47B4-A0F1-783578624F52Q30433670-A3915880-6002-49A0-99B9-508C7DFD4785Q33208591-ACC0F119-66F0-4C89-867D-BDED75AAF578Q33378927-19810C08-13F3-480A-BBB2-1F267B557881Q33510328-87C6AEDF-156C-49D5-8508-E4366BDEDEA9Q33737744-A71146CC-73C2-4AA1-B425-07ECB317A581Q33871943-8BFCA89B-1C91-4EB3-8EBB-14AEA2C8D9E9Q33906748-5A6A01E0-4F28-47EB-A743-A964C062EE4CQ33999018-E2714811-2014-4C73-8381-CA6C312195AEQ34204598-1EF7EAAE-6C17-4A67-B933-28DE1795C3DCQ34271924-92397AD6-B38D-4EEE-B889-0CCA16A82FF8Q34417996-A05CE668-5A27-4137-B561-D3FEB96E4E7EQ34611212-B429B6F3-52C5-4310-9B0C-80A8D1227973Q34611801-32375289-40D7-450F-8099-5235098637B7Q34915389-F5EC4C1A-73B6-47D2-8447-FED2F83CC65AQ35098872-C7D35EEC-96AF-49C4-8D54-E10CF20BEDABQ35163252-43813453-BE68-41EB-A52D-7FB53CCCFBEDQ35584399-BF51149C-F863-4841-8B81-FFAFA1B4A88CQ35594873-00FD6728-D1D9-4262-8D5B-D789C5A99045Q35801318-B7269E11-713F-4831-AA88-69F210D5D2C3Q35865061-7ACE5192-CFEC-4D24-922B-7B556F2765F9Q35945262-6F74E6CE-4108-4A7D-B938-1B7F907FD5CFQ35975007-A2A3500D-CDF4-4ADD-9AF1-5768FF02D2F3Q36203343-6E333390-8B3E-4CCA-A7CF-EA33B1C05354Q36255706-7E494469-4C8E-4F00-BE9F-C32A76AF32F6Q36372894-64E404F2-F371-4090-9F55-036AF50AD336Q36555662-4B966228-0792-423D-BCD9-C2847D295DCEQ36609596-772C5484-F4BC-4E5E-BEE7-362898617F74Q36630732-BF951F9C-9626-48F0-9D12-40313B4C80EBQ36714374-65CE8899-090C-485E-88F2-9F96E8CD49D5Q36742357-457227F3-9D15-40B7-9F7A-B9063A989955Q36758596-D999333E-BB7D-416D-AA54-5ED6EDAE435FQ36957962-6A2406A7-0DA6-4E3F-A032-F8F11207E924Q36995686-8F046682-3D18-430C-9987-2EC621F18E05
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Epothilones: mechanism of action and biologic activity
@ast
Epothilones: mechanism of action and biologic activity
@en
Epothilones: mechanism of action and biologic activity
@nl
type
label
Epothilones: mechanism of action and biologic activity
@ast
Epothilones: mechanism of action and biologic activity
@en
Epothilones: mechanism of action and biologic activity
@nl
prefLabel
Epothilones: mechanism of action and biologic activity
@ast
Epothilones: mechanism of action and biologic activity
@en
Epothilones: mechanism of action and biologic activity
@nl
P2093
P3181
P356
P1476
Epothilones: mechanism of action and biologic activity
@en
P2093
Eric H Rubin
Michael P Kane
Susan Goodin
P304
P3181
P356
10.1200/JCO.2004.12.001
P407
P577
2004-05-15T00:00:00Z